In this study, we report the results of the epidemiological analysis of Clostridioides difficile ribotypes (RTs) and antimicrobial susceptibility testing. Most isolates were RT027, representing 73% (84/115) of isolates. No isolates with reduced susceptibility to fidaxomicin were found; however, 38 (33.04%) isolates had reduced susceptibility to metronidazole, and 7 isolates (6.1%) had reduced susceptibility to vancomycin. These findings highlight the need for continuous surveillance of C. difficile RTs and antimicrobial susceptibility testing.
CouturierJ., DaviesK., GateauC., and BarbutF.. 2018. Ribotypes and new virulent strains across Europe. Adv. Exp. Med. Biol. 1050:45–58.
3.
OforiE., RamaiD., DhawanM., MustafaF., GasperinoJ., and ReddyM.. 2018. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J. Hosp. Infect. 99:436–442.
4.
AlamM.J., WalkS.T, EndresB.T, et al.2017. Community environmental contamination of toxigenic Clostridium difficile. Open Forum Infect. Dis. 4:ofx018.
5.
McDonaldL.C., GerdingD.N, JohnsonS., et al.2018. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66:e1–e48.
6.
Martinez-MelendezA., Tijerina-RodriguezL., Morfin-OteroR., et al.2018. Circulation of highly drug-resistant Clostridium difficile ribotypes 027 and 001 in two tertiary-care hospitals in Mexico. Microb. Drug Resist. 24:386–392.
7.
Tijerina-RodriguezL., Villarreal-TrevinoL., BainesS.D, et al.2019. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates. PLoS One, 14:e0220671.
8.
PerssonS., TorpdahlM., and OlsenK.E.. 2008. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin. Microbiol. Infect. 14:1057–1064.
9.
PerssonS., JensenJ.N, and OlsenK.E.. 2011. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC. J. Clin. Microbiol. 49:4299–4300.
10.
BidetP., BarbutF., LalandeV., BurghofferB., and PetitJ.C.. 1999. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol. Lett. 175:261–266.
11.
FalconeM., TiseoG., IraciF., et al.2019. Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clin. Microbiol. Infect. 25:474–480.
12.
ClementsA.C., MagalhaesR.J, TatemA.J, PatersonD.L, and RileyT.V.. 2010. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect. Dis. 10:395–404.
13.
KrutovaM., MatejkovaJ., DrevinekP., KuijperE.J, and NycO.. 2017. Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur. J. Clin. Microbiol. Infect. Dis. 36:2251–2258.
14.
MagnussonC., WulltM., LofgrenS., IverothP., AkerlundT., and MatussekA.. 2013. Ribotyping of Clostridium difficile strains associated with nosocomial transmission and relapses in a Swedish County. APMIS. 121:153–157.
15.
NovakA., SpigagliaP., BarbantiF., Goic-BarisicI., and TonkicM.. 2014. First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital. Anaerobe, 30:18–23.
16.
KrutovaM., MatejkovaJ., DrevinekP., KuijperE.J, and NycO., study group. 2017. Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur. J. Clin. Microbiol. Infect. Dis. 36:2251–2258.
17.
NovakovaE., StefkovicovaM., KopilecM.G, et al.2020. The emergence of Clostridium difficile ribotypes 027 and 176 with a predominance of the Clostridium difficile ribotype 001 recognized in Slovakia following the European standardized Clostridium difficile infection surveillance of 2016. Int. J. Infect. Dis. 90:111–115.
18.
KarlowskyJ.A., AdamH.J, BaxterM.R, et al.2020. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017. J. Antimicrob. Chemother. 75:1824–1832.
19.
DaviesK.A., AshwinH., LongshawC.M, BurnsD.A, DavisG.L, and WilcoxM.H, EUCstudy groupLID. 2016. Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill. 21:1560–1570.
20.
FreemanJ., VernonJ., PillingS., et al.2020. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study. Eur. J. Clin. Microbiol. Infect. Dis. 39:169–177.
21.
KatoH., SenohM., HondaH., et al.2019. Clostridioides (Clostridium) difficile infection burden in Japan: a multicenter prospective study. Anaerobe, 60:102011.
22.
SnydmanD.R., McDermottL.A, JenkinsS.G, et al.2020. Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016. Anaerobe, 63:102185.
23.
BauerM.P., NotermansD.W, van BenthemB.H, et al.2011. Clostridium difficile infection in Europe: a hospital-based survey. Lancet, 377:63–73.
24.
GoorhuisA., DebastS.B, van LeengoedL.A, et al. 2008. Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs? J. Clin. Microbiol. 46:1157; author reply 8.
25.
SandellS., RashidM.U, Jorup-RonstromC., EllstromK., NordC.E, and WeintraubA.. 2016. Clostridium difficile recurrences in Stockholm. Anaerobe, 38:97–102.
26.
EyreD.W., DaviesK.A, DavisG., et al.2018. Two distinct patterns of Clostridium difficile diversity across Europe indicating contrasting routes of spread. Clin. Infect. Dis. 67:1035–1044.
27.
FreemanJ., VernonJ., MorrisK., et al. 2015. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin. Microbiol. Infect. 21:248.e9–248.e16.
28.
FreemanJ., PillingS., VernonJ., and WilcoxM.H.. 2017. In vitro activities of MCB3681 and eight comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread. Antimicrob. Agents Chemother. 61:e02077-16.
29.
NorenT., JohanssonK., and UnemoM.. 2014. Clostridium difficile PCR ribotype 046 is common among neonatal pigs and humans in Sweden. Clin. Microbiol. Infect. 20:O2–O6.
30.
HerbertR., HatcherJ., JauneikaiteE., et al.2019. Two-year analysis of Clostridium difficile ribotypes associated with increased severity. J. Hosp. Infect. 103:388–394.
31.
HopmanN.E., OorburgD., SandersI., KuijperE.J, and LipmanL.J.. 2011. High occurrence of various Clostridium difficile PCR ribotypes in pigs arriving at the slaughterhouse. Vet. Q. 31:179–181.
